An international, randomized, placebo-controlled, double-blind phase III study (MONET1) of motesanib plus carboplatin/paclitaxel (C/P) in patients with advanced nonsquamous non-small cell lung cancer (NSCLC).

G. Scagliotti; I. Vynnychenko; Y. Ichinose; K. Park; K. Kubota; F. H. Blackhall; R. Pirker; R. Galiulin; T. Ciuleanu; O. Sydorenko; M. Dediu; Z. Papai-Szekely; N. Martinez Banaclocha; S. McCoy; B. Yao; Y. J. Hei; D. R. Spigel

doi:10.1200/jco.2011.29.15_suppl.lba7512

An international, randomized, placebo-controlled, double-blind phase III study (MONET1) of motesanib plus carboplatin/paclitaxel (C/P) in patients with advanced nonsquamous non-small cell lung cancer (NSCLC).

Journal of Clinical Oncology ◽

10.1200/jco.2011.29.15_suppl.lba7512 ◽

2011 ◽

Vol 29 (15_suppl) ◽

pp. LBA7512-LBA7512 ◽

Cited By ~ 4

Author(s):

G. Scagliotti ◽

I. Vynnychenko ◽

Y. Ichinose ◽

K. Park ◽

K. Kubota ◽

...

Keyword(s):

Lung Cancer ◽

Small Cell Lung Cancer ◽

Cell Lung Cancer ◽

Small Cell ◽

Phase Iii ◽

Small Cell Lung ◽

Double Blind ◽

Phase Iii Study

Download Full-text

Correction: Efficacy and Safety of the Biosimilar ABP 215 Compared with Bevacizumab in Patients with Advanced Nonsquamous Non–small Cell Lung Cancer (MAPLE): A Randomized, Double-blind, Phase III Study

Clinical Cancer Research ◽

10.1158/1078-0432.ccr-19-1098 ◽

2019 ◽

Vol 25 (10) ◽

pp. 3193-3193

Author(s):

Nicholas Thatcher ◽

Jerome H. Goldschmidt ◽

Michael Thomas ◽

Michael Schenker ◽

Zhiying Pan ◽

...

Keyword(s):

Lung Cancer ◽

Small Cell Lung Cancer ◽

Cell Lung Cancer ◽

Small Cell ◽

Phase Iii ◽

Efficacy And Safety ◽

Small Cell Lung ◽

Double Blind ◽

Phase Iii Study

Download Full-text

6518 ORAL Subgroup results from a randomised, double-blind, multicentre phase III study of bevacizumab in combination with cisplatingemcitabine in chemotherapy-naive patients with advanced or recurrent non-squamous non-small cell lung cancer (NSCLC): study BO17704

European Journal of Cancer Supplements ◽

10.1016/s1359-6349(07)71346-0 ◽

2007 ◽

Vol 5 (4) ◽

pp. 362 ◽

Cited By ~ 3

Author(s):

W. Eberhardt ◽

M. Reck ◽

J. vonPawel ◽

P. Zatloukal ◽

R. Ramlau ◽

...

Keyword(s):

Lung Cancer ◽

Small Cell Lung Cancer ◽

Cell Lung Cancer ◽

Small Cell ◽

Phase Iii ◽

Small Cell Lung ◽

Double Blind ◽

Multicentre Phase ◽

Phase Iii Study

Download Full-text

A randomized, double-blind, phase III study comparing two doses of erlotinib for second-line treatment of current smokers with advanced non-small-cell lung cancer (CurrentS)

Lung Cancer ◽

10.1016/j.lungcan.2016.06.019 ◽

2016 ◽

Vol 99 ◽

pp. 94-101 ◽

Cited By ~ 7

Author(s):

Egbert F. Smit ◽

Yi-Long Wu ◽

Radj Gervais ◽

Caicun Zhou ◽

Enriqueta Felip ◽

...

Keyword(s):

Lung Cancer ◽

Small Cell Lung Cancer ◽

Cell Lung Cancer ◽

Small Cell ◽

Phase Iii ◽

Line Treatment ◽

Second Line ◽

Small Cell Lung ◽

Double Blind ◽

Phase Iii Study

Download Full-text

An international, multicenter, randomized, double-blind phase III study of maintenance belagenpumatucel-l in non-small cell lung cancer (NSCLC): Updated analysis of patients enrolled within 12 weeks of completion of chemotherapy.

Journal of Clinical Oncology ◽

10.1200/jco.2014.32.15_suppl.8056 ◽

2014 ◽

Vol 32 (15_suppl) ◽

pp. 8056-8056 ◽

Cited By ~ 8

Author(s):

Lyudmila Bazhenova ◽

Giuseppe Giaccone ◽

John J. Nemunaitis ◽

Erzsébet Juhász ◽

Rodryg Ramlau ◽

...

Keyword(s):

Lung Cancer ◽

Small Cell Lung Cancer ◽

Cell Lung Cancer ◽

Small Cell ◽

Phase Iii ◽

Small Cell Lung ◽

Double Blind ◽

Phase Iii Study ◽

International Multicenter

Download Full-text

Efficacy and safety results from CurrentS, a double-blind, randomized, phase III study of second-line erlotinib (150 mg versus 300 mg) in current smokers with advanced non-small cell lung cancer (NSCLC).

Journal of Clinical Oncology ◽

10.1200/jco.2014.32.15_suppl.8046 ◽

2014 ◽

Vol 32 (15_suppl) ◽

pp. 8046-8046 ◽

Cited By ~ 1

Author(s):

Egbert F. Smit ◽

Radj Gervais ◽

Caicun Zhou ◽

Enriqueta Felip ◽

Ji Feng Feng ◽

...

Keyword(s):

Lung Cancer ◽

Small Cell Lung Cancer ◽

Cell Lung Cancer ◽

Small Cell ◽

Phase Iii ◽

Second Line ◽

Efficacy And Safety ◽

Small Cell Lung ◽

Double Blind ◽

Phase Iii Study

Download Full-text

Treatment Rationale Study Design for the MetLung Trial: A Randomized, Double-Blind Phase III Study of Onartuzumab (MetMAb) in Combination With Erlotinib Versus Erlotinib Alone in Patients Who Have Received Standard Chemotherapy for Stage IIIB or IV Met-Positive Non–Small-Cell Lung Cancer

Clinical Lung Cancer ◽

10.1016/j.cllc.2012.05.009 ◽

2012 ◽

Vol 13 (6) ◽

pp. 500-504 ◽

Cited By ~ 61

Author(s):

David R. Spigel ◽

Martin J. Edelman ◽

Tony Mok ◽

Kenneth O'Byrne ◽

Luis Paz-Ares ◽

...

Keyword(s):

Lung Cancer ◽

Small Cell Lung Cancer ◽

Study Design ◽

Cell Lung Cancer ◽

Small Cell ◽

Phase Iii ◽

Small Cell Lung ◽

Standard Chemotherapy ◽

Double Blind ◽

Phase Iii Study

Download Full-text

Rationale and study design of ARCHER: a randomized, double-blind, Phase III study of dacomitinib versus erlotinib for advanced non-small-cell lung cancer

Clinical Investigation ◽

10.4155/cli.12.137 ◽

2013 ◽

Vol 3 (1) ◽

pp. 29-35 ◽

Cited By ~ 1

Author(s):

Michael Boyer ◽

Pasi Antero Jänne ◽

Tony Mok ◽

Kenneth O’Byrne ◽

Luis Paz-Ares ◽

...

Keyword(s):

Lung Cancer ◽

Small Cell Lung Cancer ◽

Study Design ◽

Cell Lung Cancer ◽

Small Cell ◽

Phase Iii ◽

Small Cell Lung ◽

Double Blind ◽

Phase Iii Study

Download Full-text

Efficacy and Safety of the Biosimilar ABP 215 Compared with Bevacizumab in Patients with Advanced Nonsquamous Non–small Cell Lung Cancer (MAPLE): A Randomized, Double-blind, Phase III Study

Clinical Cancer Research ◽

10.1158/1078-0432.ccr-18-2702 ◽

2019 ◽

Vol 25 (7) ◽

pp. 2088-2095 ◽

Cited By ~ 12

Author(s):

Nicholas Thatcher ◽

Jerome H. Goldschmidt ◽

Michael Thomas ◽

Michael Schenker ◽

Zhiying Pan ◽

...

Keyword(s):

Lung Cancer ◽

Small Cell Lung Cancer ◽

Cell Lung Cancer ◽

Small Cell ◽

Phase Iii ◽

Efficacy And Safety ◽

Small Cell Lung ◽

Double Blind ◽

Phase Iii Study

Download Full-text

Magrit, a Double-Blind, Randomized, Placebo-Controlled Phase III Study to Assess the Efficacy of the Recmage-A3 + As15 Cancer Immunotherapeutic As Adjuvant Therapy in Patients with Resected Mage-A3-Positive Non-Small Cell Lung Cancer (Nsclc)

Annals of Oncology ◽

10.1093/annonc/mdu347.1 ◽

2014 ◽

Vol 25 ◽

pp. iv409 ◽

Cited By ~ 24

Author(s):

J.F. Vansteenkiste ◽

B. Cho ◽

T. Vanakesa ◽

T. De Pas ◽

M. Zielinski ◽

...

Keyword(s):

Lung Cancer ◽

Adjuvant Therapy ◽

Small Cell Lung Cancer ◽

Cell Lung Cancer ◽

Small Cell ◽

Phase Iii ◽

Small Cell Lung ◽

Double Blind ◽

Phase Iii Study ◽

Cancer Immunotherapeutic

Download Full-text

A randomized, double-blind phase III study of icotinib versus gefitinib in patients with advanced non-small cell lung cancer (NSCLC) previously treated with chemotherapy (ICOGEN).

Journal of Clinical Oncology ◽

10.1200/jco.2011.29.15_suppl.7522 ◽

2011 ◽

Vol 29 (15_suppl) ◽

pp. 7522-7522 ◽

Cited By ~ 11

Author(s):

Y. Sun ◽

Y. Shi ◽

L. Zhang ◽

X. Liu ◽

C. Zhou ◽

...

Keyword(s):

Lung Cancer ◽

Small Cell Lung Cancer ◽

Cell Lung Cancer ◽

Small Cell ◽

Phase Iii ◽

Small Cell Lung ◽

Double Blind ◽

Phase Iii Study ◽

Previously Treated

Download Full-text